Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis - PubMed (original) (raw)

Meta-Analysis

Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis

Zuhair S Natto et al. Sci Rep. 2019.

Abstract

The purpose of this systematic review and meta-analysis was to investigate omega-3 fatty acids' influence on 12 inflammatory biomarkers-LDL, HDL, total cholesterol, TG, HbA1c, Apo AI, Apo AII, Apo B, CRP, TNF-α, glucose, and fasting blood glucose among diabetic and cardiovascular disease (CVD) patients. We searched articles in six database engines, and 16 of the 696 articles reviewed met the inclusion criteria. Among these, lipid and inflammatory biomarkers investigated commonly included total cholesterol (11 studies), LDL, and TG (10 studies each). Overall, omega-3 was associated with a significant reduction in Apo AII among diabetic patients, as compared to different controls (-8.0 mg/dL 95% CI: -12.71, -3.29, p = 0.0009), triglycerides (-44.88 mg/dL 95% CI: -82.6, -7.16, p < 0.0001), HDL (-2.27 mg/dL 95% CI: -3.72, -0.83, p = 0.002), and increased fasting blood glucose (16.14 mg/dL 95% CI: 6.25, 26.04, p = 0.001). Omega-3 also was associated with increased LDL among CVD patients (2.10 mg/dL 95% CI: 1.00, 3.20, p = 0.0002). We conclude that omega-3 fatty acids may be associated with lower inflammatory biomarkers among diabetic and cardiovascular patients. Clinicians should be aware of these potential benefits; however, it is essential to recommend that patients consult with clinicians before any omega-3 intake.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1

Figure 1

PRISMA Flow diagram of the numbers of studies screened and included in the review.

Figure 2

Figure 2

Impact of omega-3 fatty acids on Apo AI, Apo AII, Apo B, and CRP among diabetic patients.

Figure 3

Figure 3

Impact of omega-3 fatty acids on total cholesterol, HDL, LDL, and triglycerides among diabetic patients.

Figure 4

Figure 4

Impact of omega-3 fatty acids on glucose, fasting blood glucose, and HbA1c among diabetic patients.

Figure 5

Figure 5

Impact of omega-3 fatty acids on Apo AI, Apo B, glucose, and TNF-α among CVD patients.

Figure 6

Figure 6

Impact of omega-3 fatty acids on total cholesterol, HDL, LDL, and triglycerides among CVD patients.

Similar articles

Cited by

References

    1. Freire MO, Van Dyke TE. Natural resolution of inflammation. Periodontology 2000. 2013;63:149–164. doi: 10.1111/prd.12034. - DOI - PMC - PubMed
    1. Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Critical reviews in oral biology and medicine: an official publication of the American Association of Oral Biologists. 2003;14:4–12. doi: 10.1177/154411130301400102. - DOI - PubMed
    1. Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nature reviews. Endocrinology. 2011;7:738–748. doi: 10.1038/nrendo.2011.106. - DOI - PubMed
    1. Hasturk H, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. Journal of immunology (Baltimore, Md.: 1950) 2007;179:7021–7029. doi: 10.4049/jimmunol.179.10.7021. - DOI - PubMed
    1. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2003;95:559–569. doi: 10.1067/moe.2003.107. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources